Bristol-Myers Squibb gets FDA approval for Augtyro for NTRK gene fusion-positive solid tumours. Skip to main content Wednesday 25 June 2025 . BlueSky linkedin youtube rss. User account menu ...

Pharma/biotech giants Pfizer PFE and Bristol Myers BMY boast of a dominant position in the lucrative oncology space. Oncology ...

A paper published by researchers at Fox Chase Cancer Center highlights the case of a patient who was diagnosed with adenoid ...

The Ministry of Food and Drug Safety noted, 'We expect this drug will provide new treatment opportunities for patients with ROS1-positive non-small cell lung cancer or solid tumors with NTRK gene ...

Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) have discovered a ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

Fusion genes, arising from abnormal chromosomal rearrangements, are gaining recognition as pivotal players in cancer ...

So most fusion power concepts rely on “enriched” lithium, where the lithium-6 content has been boosted to more than 50 per cent, and sometimes up to 90 per cent, of the total.

Subgroup analyses from both the post-MONARCH and EMBER-3 trials additionally suggest that patients benefit from abemaciclib after previous CDK4/6i exposure, regardless of ESR1 or PIK3CA mutation ...

Gene editing holds the potential of suppressing mosquito species that carry deadly diseases — and raises ethical questions.

Nobody said that commercializing fusion power would be cheap or quick. TAE Technologies said this week it raised another $150 million in a funding round that included investments from existing ...

Shares of Sarepta Therapeutics plunged Monday after the biotech drugmaker reported a second death in connection with its gene therapy for muscular dystrophy.